Research team discovers molecule that may help fight cancer drug resistance

March 14, 2014 by Diane Kukich
Zhihao Zhuang is leading a research team that has discovered that USP1-UAF1, a protein known as deubiquitinase, may be a key regulator of the DNA damage response and a target for overcoming resistance to platinum-based anticancer drugs. Credit: Evan Krape

(Medical Xpress)—There are no popularity contests for proteins, but a prevalent protein called ubiquitin drew quite a following after three scientists received the 2004 Nobel Prize in Chemistry for discovering its role in mediating protein degradation.

That ground-breaking research on ubiquitination was conducted in the 1970s and '80s, and it has since been discovered that this small protein plays a big role in cell biology, including how the human body deals with internal and external attacks on its DNA.

However, while the essential roles of ubiquitin have received a lot of attention in the decade since the Nobel was awarded, the reverse of ubiquitination, or deubiquitination, is less well understood.

Now, a group of researchers led by Zhihao Zhuang, associate professor in the Department of Chemistry and Biochemistry at the University of Delaware, has discovered that a deubiquitinase (or DUB) complex, USP1-UAF1, may be a key regulator of the DNA damage response and a target for overcoming resistance to platinum-based anticancer drugs. Their findings were published in the online version of Nature Chemical Biology on Feb. 16.

Our DNA is under constant attack by UV light, radiation, industrial carcinogens, and other environmental factors, as well as by endogenous processes such as oxidation and hydrolysis. But our bodies also have ways to repair that damage or to tolerate it temporarily until a repair strategy kicks in.

Zhuang's research group is particularly interested in a DNA damage tolerance mechanism known as translesion synthesis (TLS), in which enzymes called TLS polymerases synthesize DNA over the damaged nucleotide bases, followed by normal replication after the lesion. 

Conducting research are (from left) students Qin Liang, Mark Villamil and Christine Ott, with Zhihao Zhuang, associate professor of chemistry and biochemistry. Credit: Evan Krape

The problem is that while TLS polymerases are generally good guys, they also have a dark side—they have been implicated in making resistant to certain cancer drugs, including cisplatin, which is often used to treat testicular, bladder, and ovarian cancers that have spread.

"Cancer drugs like cisplatin work by damaging DNA and thereby preventing cancer cells from replicating the genomic DNA and dividing," Zhuang explains. "However, cancer cells quickly develop resistance to cisplatin, and we and other researchers suspect that a polymerase known as Pol η is involved in overcoming cisplatin-induced lesions."

So while Pol η is a good guy under normal circumstances—in effect, paving the way over DNA potholes until the road levels out on the other side—it becomes a bad guy when the smooth road enables cancer cells to keep traveling.

Now, Zhuang and his team have discovered a new molecule, ML323, that can inhibit processes, such as TLS, that may be hijacked by cancer cells to overcome the roadblocks on genomic DNA. 

"Using ML323, we studied the cellular response to DNA damage and revealed new insights into the role of deubiquitination in both the TLS pathway and another one called the Fanconi anemia, or FA, pathway," Zhuang says. "We're very encouraged by the fact that a single molecule is effective at inhibiting the USP1-UAF1 DUB complex and disrupting two essential DNA damage tolerance pathways."

The finding may give clinicians a new weapon in the arsenal against cancer. 

"We exposed to cisplatin alone and to a combination of cisplatin and ML323, and we achieved close to an order of magnitude reduction in EC50, a common measure of the potency of small-molecule drugs, when the combination was used," Zhuang says. "This tells us that the inhibitor effectively restores the ability of cisplatin to fight cancer cells."

"Cancer treatment is increasingly moving to combination therapies to make it more effective and less toxic to normal cells," he adds. "I think our findings from this work indicate that the USP1-UAF1 DUB inhibitor not only shows promise in fighting cancer but also can help us in investigating the complex biology of DNA damage responses."

The Nature Chemical Biology paper has been selected as a highlight by several journals since its publication online last month, and many people have contacted Zhuang to express interest in the work.

Explore further: Resistance is futile: Researchers identify gene that mediates cisplatin resistance in ovarian cancer

More information: "A selective USP1–UAF1 inhibitor links deubiquitination to DNA damage responses." Qin Liang, et al. Nature Chemical Biology (2014) DOI: 10.1038/nchembio.1455 . Received 06 July 2013 Accepted 11 December 2013 Published online 16 February 2014

Related Stories

Resistance is futile: Researchers identify gene that mediates cisplatin resistance in ovarian cancer

April 15, 2013
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...

Enhancement of chemotherapy by prevention of tumor cell repair

February 20, 2014
Chemotherapies are cancer treatments that work by inducing lesions in the DNA of tumour cells in order to inhibit their proliferation. However, the body naturally tries to repair these lesions, and thus reduces the efficacy ...

Biologists ID new cancer weakness

November 14, 2013
About half of all cancer patients have a mutation in a gene called p53, which allows tumors to survive and continue growing even after chemotherapy severely damages their DNA.

New clues may link hereditary cancer genes to increased risk of cancer from alcohol

January 23, 2014
In laboratory experiments conducted on human cell lines at the Johns Hopkins Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.